Plain Language Summary {#S0001}
======================

Laser refractive surgery is one of the most common elective eye surgical procedures in the world. Many individuals wishing to reduce their need for glasses decide to have it. Modern technology has made the procedure very safe and effective.

Most of the time, the surgery is based only on the prescription for glasses, usually determined in the office by asking patients to choose the lens that gives them the best vision (refraction). While this may be a good starting point, adjustments in the treatment to remove any irregularities in the curvature of the front surface of the eye (the cornea) may make the vision even better. Sophisticated instruments can measure the shape of the cornea in great detail. These devices produce a map of the corneal shape, called a topographic map, that resembles a contour map in geography that shows the peaks and valleys on the surface of the earth.

The FDA recently approved an excimer laser refractive treatment based on both the refraction and the corneal topography. Reported results were excellent. There are several possible methods to design the treatment, but only one was studied in the FDA clinical trial. This study was based on theoretical outcomes that might result if some alternative methods were used to design the treatment. While all results were good, the best results were found with a new software program that helps surgeons with their surgical planning.

Introduction {#S0002}
============

Most currently used refractive lasers employ wavefront-guided treatment profiles. Topography-guided treatment has traditionally been reserved for complex cases with irregular astigmatism.[@CIT0001] One topography-guided LASIK procedure (Contoura^®^ Vision, Alcon, Fort Worth, Texas, USA) has been shown to provide excellent visual outcomes in normal eyes without irregular astigmatism, with 93% of eyes achieving 20/20 or better UDVA and 34% achieving 20/12.5 or better UDVA at 12 months.[@CIT0002]

Because corneal topography does not provide any information about the refractive status of the eye, the user must enter low-order aberrations (sphero-cylindrical refraction), which are combined with high-order aberrations measured by a Placido topographer, to create a shot file designed to eliminate the refractive error of the eye by changing the corneal curvature. On the Treatment Plan page of the laser notebook, three sphero-cylindrical refractions are shown: Clinical, Measured, and Modified ([Figure 1](#F0001){ref-type="fig"}).Figure 1Treatment planning page for the WaveLight Contoura® Vision laser.

The Clinical refraction is the preoperative subjective manifest refraction. The cylinder from this entry is termed the Manifest cylinder in this report. The Measured refraction is the sphero-cylindrical correction that is necessary to neutralize regular, low-order corneal astigmatism after removal of high-order aberrations on the cornea. It is termed the Topo cylinder in this report (to distinguish it from the cylinder measured by refraction). The Topo cylinder is derived from Placido topography obtained by the WaveLight^®^ Topolyzer™ VARIO Diagnostic Device (Vario; Alcon, Ft. Worth, TX). The Modified refraction, which is entered by the user, is then combined with high-order aberrations to create the refractive ablation that is intended to correct vision. This entry is termed the Treatment refraction in this report. The WaveLight laser provides the user with the opportunity to select the Modified refraction based on the desired clinical outcome, the Manifest cylinder, the Topo cylinder, or any other factor(s).

Optimally, the Manifest and Topo cylinder will be the same or similar, but in some cases, they differ by more than a trivial amount. Possible explanations for this difference include the presence of significant high-order corneal aberrations[@CIT0003]--[@CIT0006] posterior corneal astigmatism, and lenticular astigmatism. Manifest and Topo cylinders tend to differ in eyes with high-order aberrations because the subject may choose a sphero-cylindrical refraction in an attempt to correct high-order aberrations. For example, a subjective refraction may result in cylinder that is selected by the subject in an effort to reduce the blur circle created by coma.[@CIT0004],[@CIT0005] If visually significant coma is treated by topography-guided LASIK, there is no longer a need for correction with low-order refractive cylinder when it is induced by the high-order aberrations.[@CIT0004],[@CIT0005] High-order aberrations may also produce a different subjective refractive cylinder that depends in magnitude and/or angle on the size and location of the pupil, as the pupillary opening restricts light striking the retina to portions of the cornea that may have different high-order aberrations.[@CIT0007]

During the FDA clinical trial of the Contoura, the clinical protocol required that investigators enter the Manifest refraction as the Treatment refraction during treatment planning. This requirement was based on the early report of Tan et al that good outcomes could be obtained by programming the laser with the cylinder obtained by refraction, rather than that measured by topography.[@CIT0008] Throughout the FDA study, there was good agreement between Manifest and Topo cylinder because subjects with significant corneal high-order aberrations were specifically excluded from the trial, as required by the FDA.[@CIT0002]

After approval, when the laser became widely used in clinical settings, it was used to treat eyes with more irregular topographies and greater disparity between Manifest and Topo cylinder than was encountered in the FDA clinical trial. Clinical experience after FDA approval of the laser led some to hypothesize that programming with the Manifest cylinder might not produce optimal results in eyes with significant HOA.

In 2016, Motwani reported 78% of eyes with 20/15 vision 3 months after initial treatment with the Contoura laser using the LYRA (Layer Yolked Reduction of Astigmatism) Protocol, which is based on the Topo cylinder with spherical adjustment to maintain the spherical equivalent of the manifest refraction[@CIT0004],[@CIT0009],[@CIT0010] This protocol also produced excellent Refractive Status and Vision Profile subjective patient survey outcomes.[@CIT0011]

Also in 2016, Kanellopoulos used the Topo cylinder modified to preserve the spherical equivalent of the manifest refraction to obtain 20/16 or better in 50% of eyes, compared to 22% of eyes in which manifest refraction was used to program the laser.[@CIT0012]

In a more recent study, Wallerstein et al programmed the laser with the magnitude of the manifest cylinder and the Topo axis. They compared results to those obtained by programming the laser with the manifest cylinder and the manifest cylinder axis. They found that the outcomes using the Topo axis were inferior to those obtained with the cylinder axis measured by the manifest refraction.[@CIT0006]

These published findings and the unpublished experiences of others, including the authors of this paper, have led to further discussions about whether the method of programming the laser that was used during the FDA clinical trial produces optimal outcomes.

The purpose of this study was to analyze retrospectively the sphero-cylindrical refractive outcome when there was a disparity between the Manifest cylinder measured preoperatively and the Topo cylinder measured by topography (\>/= 0.50 D and/or \>/= 10 degrees). Known outcomes with actual programming strategies were used to simulate outcomes that would have been obtained by back-calculation using three different refractive inputs for treatment planning: Manifest cylinder (based on the clinical refraction), Topo cylinder (based on Placido topography obtained with the Vario topographer), and Phorcides cylinder (calculated using the Phorcides Analytic Engine, Phorcides LLC, North Oaks MN).

Methods {#S0003}
=======

This study was determined to be exempt from IRB review according to 45 CFR 46.101(b)(4) by Salus IRB.

Refractive and treatment data from cases in which the preoperative manifest cylinder and topographic cylinder differed by 0.50D or more in magnitude and/or 10 degrees or more in orientation were contributed retrospectively by 6 users of the Contoura^®^ Vision at 5 sites. Three-month postoperative examinations (range, 75--197 days) were completed before January 31, 2018. There was variability in the way investigators chose the cylindrical correction to be entered as the Treatment refraction, as this decision was left up to the discretion of the investigator ([Table 1](#T0001){ref-type="table"}).Table 1Treatment Method Actually Used at Each SiteSiteEyesMethod110LYRA^a^214LYRA36LYRA49MR^b^58LYRA65MR[^1]

Subjects were stratified on the basis of the vector difference between Manifest and Topo cylinder with a cutoff of 0.75 D, as that yielded approximately half the data points in each group. They are referred to as the High (\>0.75D difference; 33 eyes) and Low (≤0.75D difference; 19 eyes) groups in subsequent analyses.

Overall Difference from "Best" {#S0003-S2001}
------------------------------

The "Best" correction is the correction that produced, or would theoretically have produced, a zero cylinder postoperative outcome. It is the vector sum of the actual Treatment cylinder entered by the surgeon into the Modified blanks on the Treatment Design screen ([Figure 1](#F0001){ref-type="fig"}) and the refractive cylinder measured 3 months postoperatively.

Calculation of Theoretical Results {#S0003-S2002}
----------------------------------

The theoretical sphero-cylindrical refractive error that would have resulted if Manifest, Topo, or Phorcides cylinder had been entered as the Treatment cylinder was calculated by vector subtraction of the three theoretical cylinder entries from the Best correction. In some cases, the Treatment cylinder was the same as the Manifest or Topo cylinder. Results are presented with descriptive analysis and double-angle vector plots. Statistical significance was determined by analysis of variance (ANOVA).

Results {#S0004}
=======

[Table 2](#T0002){ref-type="table"} shows refractive details of the eyes included in this investigation. There was no statistically significant difference between the High and Low groups with regard to any of the preoperative variables. [Table 3](#T0003){ref-type="table"} shows the breakdown of the difference in astigmatism magnitude and orientation between the preoperative manifest and the topography-based values. As can be seen, half the eyes (26/52) differed by less than 20 degrees in orientation and 1.0D in magnitude.Table 2Refractive Data SummaryMeanSDMinimumMaximumpAge32.738.011950Preop CDVA^a^ (logMAR)−0.080.06−0.1250.000 High−0.080.06−0.1250.0000.35 Low−0.090.06−0.1250.000Preop MR Sphere (D)−3.641.78−8.000−0.500 High−3.541.67−6.750−0.5000.59 Low−3.822.00−8.000−1.000Preop MR Cylinder (D)−0.890.56−2.7500.000 High−0.950.64−2.7500.0000.38 Low−0.800.40−1.7500.000Treatment Sphere (D)−3.621.66−7.550−0.600 High−3.561.56−6.500−0.8700.72 Low−3.731.87−7.550−0.600Treatment Cylinder (D)−1.010.53−2.4300.000 High−1.060.52−2.430−0.4000.38 Low−0.930.56−2.0100.000Postop UCDVA^b^(logMAR)−0.070.09−0.3000.100Postop CDVA (logMAR)−0.110.07−0.3000.000[^2] Table 3Difference in Refractive and Topographic Astigmatism Angle and MagnitudeDifference in Magnitude (D)Difference in Orientation (Degrees)≤1011 to 2021 to 4041 to 6061 to 80Total≤0.501^a^5431140.51 \< and ≤ 1.00155711291.01 \< and ≤ 1.506171.51 \< and ≤ 2.00112[^3]

[Figure 2](#F0002){ref-type="fig"} shows uncorrected visual acuities at 3 months, and [Figure 3](#F0003){ref-type="fig"} shows the change in visual acuity from the preoperative examination to 3 months postoperatively. No complications or adverse events were observed in any of the eyes included in this study.Figure 2Cumulative uncorrected visual acuities at 3 months.Figure 3Change in corrected distance visual acuity from preoperative exam to the 3-month postoperative exam.

Manifest {#S0004-S2001}
--------

[Figure 4](#F0004){ref-type="fig"} shows a double-angle plot of the calculated error vectors that would theoretically have been obtained if the Manifest cylinder had been entered as the Treatment refraction. The error vectors tend to be with the rule (centroid: −0.43, 0.11). Summary data are shown in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}. The mean calculated magnitude of the error vector was 0.56 ± 0.42 D (mean ± SD; [Table 4](#T0004){ref-type="table"}). It was significantly greater in the High group (0.70 D) compared to the Low group (0.33 D; p = 0.002). In 15% of cases (8/52), the Manifest error vector was greater than 1.0D, and all of these were in the High group ([Table 5](#T0005){ref-type="table"}).Table 4Centroids and Error Magnitude for Expected or Actual Cylinder Error by MethodMethodGroupX CoordinateY CoordinateMagnitude (D)Mean Error (D)ManifestHigh−0.48 \[0.47\]^a^0.15 \[0.28\]0.510.70 \[0.46\]Low−0.17 \[0.25\]−0.07 \[0.15\]0.180.33 \[0.23\]All−0.43 \[0.47\]0.11 \[0.28\]0.440.56 \[0.42\]TopoHigh0.49 \[0.37\]0.03 \[0.31\]0.490.47 \[0.35\]Low0.36 \[0.33\]−0.08 \[0.20\]0.370.48 \[0.31\]All0.37 \[0.36\]0.02 \[0.28\]0.370.47 \[0.33\]PhorcidesHigh−0.17 \[0.34\]0.10 \[0.33\]0.190.48 \[0.28\]Low−0.01 \[0.28\]−0.08 \[0.17\]0.080.26 \[0.20\]All−0.15 \[0.36\]0.06 \[0.28\]0.160.39 \[0.28\][^4] Table 5Magnitude of Actual and Calculated Error Vectors by MethodMethodMagnitude of Error Vectors (D)≤0.25≤0.50≤0.75≤1.00\>1.00Manifest16^a^2936448Topo173043502Phorcides193645502[^5] Figure 4Error vectors: difference between calculated Manifest and Best outcomes. Ellipses are the centroid ± SD for the low (![](OPTH-14-1091-i0001.jpg){#ILF0001}) and high (- - -) groups.

Topo {#S0004-S2002}
----

[Figure 5](#F0005){ref-type="fig"} shows a double-angle plot of the calculated error vectors that would have been obtained if the Topo cylinder had been entered as the Treatment refraction. The error vectors tend to be against the rule (centroid: 0.37, 0.02). Summary data are shown in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}. The mean calculated error vector was 0.47 ± 0.33 D (mean ± SD; [Table 4](#T0004){ref-type="table"}). There was no significant difference between the magnitude in the High (0.47 D) and Low (0.48 D) groups. The magnitude of the error vector was greater than 1.0 D in 4% (2/52) of cases -- one in the High group and one in the Low group ([Table 5](#T0005){ref-type="table"}).Figure 5Error vectors: difference between Topo and Best outcomes. Ellipses are the centroid ± SD for the low (![](OPTH-14-1091-i0002.jpg){#ILF0002}) and high (- - -) groups.

Phorcides {#S0004-S2003}
---------

[Figure 6](#F0006){ref-type="fig"} shows a double-angle plot of the calculated error vectors that would have been obtained if the cylinder derived from the Phorcides software had been entered as the Treatment refraction. The error vectors tend to be with the rule, but the deviation from the origin is minimal (centroid: −0.15, 0.06). Summary data are shown in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}. The mean calculated error vector was 0.39 ± 0.28 D (mean ± SD; [Table 4](#T0004){ref-type="table"}). The mean error vector magnitude in the Phorcides Low group was significantly lower than for the Manifest and Topo Low groups (0.26 D vs 0.48 D and 0.33 D; p \< 0.01). The mean error magnitude in the Phorcides High group is nearly 0.25 D lower than for the Manifest High group (0.48 D vs 0.70 D; p\< 0.01; [Table 4](#T0004){ref-type="table"}), and the same as for the Topo High group. There were two cases of Phorcides error being greater than 1.0 D, both occurring when the vector difference between Manifest and Topo was \>0.75 D ([Table 5](#T0005){ref-type="table"}).Figure 6Error vectors: difference between Phorcides and Best outcomes. Ellipses are the centroid ± SD for the low (![](OPTH-14-1091-i0003.jpg){#ILF0003}) and high (- - -) groups.

Discussion {#S0005}
==========

Topography-guided corneal refractive surgery has historically been used as a "repair procedure" for the treatment of eyes with naturally-occurring corneal irregular astigmatism,[@CIT0001],[@CIT0012]--[@CIT0014] complications of corneal refractive surgery,[@CIT0001],[@CIT0015]-[@CIT0022] corneal transplants,[@CIT0016],[@CIT0018],[@CIT0020],[@CIT0023],[@CIT0024] and other corneal conditions.[@CIT0001],[@CIT0016],[@CIT0018] Topography-guided PRK has also been used for the treatment of corneal ectatic disorders in conjunction with corneal crosslinking with riboflavin and ultraviolet light[@CIT0025]--[@CIT0027] and to prevent hyperopic regression following hyperopic LASIK.[@CIT0028] Topography-guided LASIK also produces excellent outcomes for the treatment of refractive errors in otherwise normal eyes.[@CIT0002],[@CIT0008] In one comparative study, topography-guided LASIK was found to produce lower high-order aberrations than wavefront-guided treatment.[@CIT0029]

Requests for inclusion of eyes with naturally occurring, surgically induced, or pathological irregular astigmatism in FDA clinical trials were denied by the FDA. As a result, the FDA study does not provide prospective clinical trial outcomes for the treatment of eyes with even minimal corneal topographic abnormalities.[@CIT0002] In eyes such as this, which are frequently encountered in clinical practice, a disparity between astigmatism that is measured by refraction (Manifest) and that measured by topography (Topo) is more likely to occur.[@CIT0002] This creates a dilemma for the refractive surgeon using the WaveLight Contoura^®^ Vision laser, because the surgeon must choose the sphero-cylindrical refraction to be entered in the treatment plan without reliable guidance from carefully conducted clinical trials.

Although some recent studies have achieved results similar to those obtained in the FDA trial,[@CIT0030],[@CIT0031] some of the authors of this report (MCL, TPL), as well as several other investigators,[@CIT0032]--[@CIT0034] have been unable to obtain the excellent postoperative visual acuities obtained during the FDA trial when the same treatment protocol was applied to eyes encountered in routine clinical practice. Various alternative strategies have been proposed, therefore, to determine the appropriate laser entry for the Treatment sphero-cylindrical refraction.[@CIT0004],[@CIT0006],[@CIT0009],[@CIT0010],[@CIT0012]

The current study was designed to address the question of how to program the WaveLight Contoura^®^ Vision laser to produce optimal refractive outcomes for eyes in which there is a disparity between Manifest and Topo refractions. The most appropriate outcome measures for this determination would be uncorrected visual acuity and visual symptoms. Unfortunately, is it not possible to simulate the visual acuity and visual symptoms that would have been obtained if a refraction other than the one that was used to treat the patient had been applied.

One published study does examine retrospectively the planning strategy used among eyes gaining a line of best-corrected vision, but the variability and complexity of the strategy make it difficult to plan prospectively.[@CIT0035] We chose the actual and calculated sphero-cylindrical refractive outcome as our primary outcome measure for this analysis. Although imperfect, this provides a method to compare the actual outcome obtained with the surgeon's selected treatment strategy and the theoretical, calculated outcome that might have been obtained with alternative methods.

Overall, the visual outcomes in the subjects we studied were excellent ([Figure 2](#F0002){ref-type="fig"}), with a tendency for increased uncorrected distance visual acuity (UCDVA; [Figure 3](#F0003){ref-type="fig"}) and no complications; however, a small, measurable residual refractive error remained in many of them. None of the 3 treatment strategies we tested would have completely eliminated postoperative refractive error for all patients. However, the results strongly suggest that the other strategies that we tested will produce outcomes that are superior to those obtained when the Manifest refraction is entered as the Treatment refraction, as was done in the FDA clinical trial. It is possible that consideration of posterior corneal and lenticular astigmatism that is inherent to Phorcides may provide an advantage of this method over alternatives, but this advantage seems to be less apparent with higher corrections, as was seen in the Topo High and Phorcides High groups.

Our results were obtained from theoretical calculations of outcomes in a small series of eyes, rather than actual results from a head-to-head comparison of laser programming strategies. Our conclusions were also based on calculated cylindrical outcomes, rather than UCDVA. A larger, prospective, multi-center clinical trial that includes UCDVA as a primary outcome variable should lead to further refinement of the appropriate strategy for determining the Treatment refraction for use with the Contoura laser for topography-guided LASIK in clinical, post-approval use for eyes routinely encountered in a commercial LASIK practice. In addition, a greater number of eyes might allow for more detailed sub-analyses, such as those necessary to determine whether the orientation of preoperative manifest or topographic astigmatism might have an effect on the optimal laser programming strategy. Finally, it is yet unknown whether correcting posterior astigmatism on the anterior cornea will lead to a longer-term compensatory effect by the epithelium affecting the clinical outcome. All of these factors must be investigated in well-designed, prospective clinical trials.
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[^1]: **Notes:** ^a^Layered Yolked Reduction of Astigmatism.[@CIT0004] bManifest refraction.

[^2]: **Notes:** ^a^Corrected distance visual acuity. ^b^Uncorrected distance visual acuity.

[^3]: **Note:** ^a^Number of eyes.

[^4]: **Note:** ^a^Value\[SD\].

[^5]: **Notes:** ^a^Number of eyes.
